BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

BACKGROUND: Mutated epidermal growth factor receptor (EGFR) is one of the most successful targets in cancer targeted therapy. While this treatment has benefited many patients with an activating EGFR mutation (EGFRm), almost all those who initially benefited will eventually develop acquired drug resi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Biosci
Main Authors: Zhan, Yihong, Wang, Yue, Qi, Miao, Liang, Panpan, Ma, Yu, Li, Ting, Li, Hui, Dai, Congmei, An, Zhifeng, Qi, Yitao, Wu, Hongmei, Shao, Huanjie
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://ncbi.nlm.nih.gov/pubmed/31367332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0322-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki